Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE®
SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRa) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.
FRa is a biomarker commonly expressed in patients with ovarian cancer. FRa establishes patient eligibility for ELAHERE® (“mirvetuximab soravtansine-gynx”), the only FDA-approved drug indicated for patients who are FRa-positive and resistant to platinum-based chemotherapy. FRa is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer. According to the SORAYA study, 36% of patients screened were found to have high tumor FRa expression, representing a significant proportion of patients with ovarian cancer who could potentially benefit from MIRV-based therapy.
“FRa, alongside germline and homologous recombination deficiency status, can be a powerful biomarker for patients with ovarian cancer to create a comprehensive treatment plan,” said Ramez N. Eskander, associate professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego School of Medicine. “Patients will benefit from Myriad’s addition of FRa testing to their Precise Oncology Solutions portfolio to help improve outcomes for this patient group.”
FRa is available immediately and can be ordered alongside other companion diagnostic test offerings through the Myriad ordering potal. For a streamlined workflow and quicker path to making treatment decisions, oncologists can receive germline, HRD, FRa biomarker and tumor testing results from a single laboratory.
“The expansion of our portfolio with FRa highlights our commitment to continually growing and innovating to support oncologists with comprehensive, data-driven genetic insights that can better inform treatment decisions for their patients,” said Michael Lyons, general manager of Oncology, Myriad Genetics.
About Myriad Genetics
Myriad, the Myriad logo, and Precise are registered trademarks or trademarks of Myriad Genetics, Inc. All third-party marks—® and ™—are the property of their respective owners.
ELAHERE® is a registered trademark of ImmunoGen, Inc.
Safe Harbor Statement